Rodolphe Lilamand

Convergent Capital SA (CC) is a venture capital investment firm established in 2001 and located west of Paris. CC manages the Convergent Technologies FCPR fund. Their international clientele comprises business angels, entrepreneurs, and institutions including public entities and financial institutions.

Aleia SAS is an AI platform that accelerates and secures all AI projects. The company is based in Paris, France. The platform is designed for all sectors of activity and is sovereign and secure. The platform was created to industrialize AI projects and promote collaboration among teams. It was founded in 2021 by Antoine Couret, who is also the CEO.

Isocell SA operates as a holding company with interests in the manufacture of food supplements. It develops proprietary formulation for super-oxyde dismutase. The firm also targets food areas including sodas, sport drinks and dairies with wellness claims. It also engages in the ownership and operations of medical laboratories. The company was founded by Francois Vix on July 9, 2001 and is headquartered in Paris, France.

AlchiMedics SA specializes in coating technologies via electrografting. Its products enables covalent adhesion of nano to micrometric polymer-based layers on surfaces. The firm designs, develops and implements electro-grafting technology for implantable biomedical applications. The company was founded in 2007 and is headquartered in Grenoble, France.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Convertigo SAS provides Internet related software. It delivers a secured and scalable disruptive all-in-one solution, integrating rapid cross platform mobile development tools and a powerful MBaaS covering challenging backend enablement, featuring a middleware optimized for mobility. The company was founded by Olivier Picciotto and Jean-Michel Cohen in 1994 and is headquartered in Orsay, France.

Telecom Technologies Transfert SAS (3T) is an independent venture capital firm headquartered in Paris, France. The firm was founded in 2010.

Mckinsey & Co. SAS provides business and management consulting services. The company is headquartered in Paris, France.

Eptica SA provides online customer service software. It offers solution for customer interaction management including web self-service, social customer service, email management, chat, fax-letter-short message service, and knowledge management for customer service. The company was founded in 2001 and is headquartered in Boulogne-Billancourt, France.

Innes SA manufactures audio-visual hardware equipment. The firm operates at all stages of the distribution of the image and sound in the audiovisual and digital signage and IPTV. Its products include PlugnCast CMS, PlayZillaApp, SignMeeting App and Devices with Gekkota. The company was founded by Olivier David and Franck Dupin in 2005 and is headquartered in Rennes, France.